Work
Order #1

    Dated
November 9, 2007

    


    The
services described herein will be provided in accordance with the terms and
conditions of the Master Services Agreement, dated August 24, 2007, between
AAIPharma Inc., on behalf of itself and its subsidiaries (collectively,
‘AAIPharma’) and YM Biosciences USA Inc. (hereinafter referred to as “YMB
USA”).

    


    The
following documents are attached to this Work Order and shall be incorporated
herein:

    


    
      	
              Attachment
    I

            	
              Final Scope of Work, including
      the description of Services to be provided and
    timeline

            


    

    


    
      	
              Attachment
    II

            	
              Budget and Payment Terms for the
      Final Scope of Work

            


    

    


    All terms
and conditions provided in the Master Services Agreement executed by the parties
with an Effective Date of August 24, 2007 remain unmodified and in full force
and effect.

    


    ACKNOWLEDGED,
ACCEPTED AND AGREED TO:

    


    AAIPharma
Inc.

    


    
      
        	 
      	 
      	 
      
	
                Signature

              	 
      	
                Date

              
	 
      	 
      	 
      
	 
      	 
      	 
      
	
                Name

              	 
      	 
      
	 
      	 
      	 
      
	 
      	 
      	 
      
	
                Title

              	 
      	 
      


      

    

    


    YM Biosciences USA
Inc.  

    


    
      
        	
                /s/ David G.P. Allan

              	 
      	
                [ILLEGIBLE]

              
	
                Signature

              	 
      	
                Date

              
	 
      	 
      	 
      
	
                David G.P. Allan

              	 
      	 
      
	
                Name

              	 
      	 
      
	 
      	 
      	 
      
	
                CHAIR & CEO

              	 
      	 
      
	
                Title

              	 
      	 
      


      

    

     

    
      
         


      

      
         


        
          

        

      

      
         


      

    


    ATTACHMENT
I to Work Order #1

    Final
Scope of Work

    


    Protocol No. YMB USA1000/009
entitled “Phase II Study of Safety and Efficacy of Nimotuzumab (TheraCIM®) In
Pediatric Patients with Recurrent Diffuse Intrinsic Pontine Glioma”

    


    SCOPE
OF WORK:

    


    
      
        
          	
                  ·

                	
                  Project
      Management (USA)

                	
                  ·

                	
                  Medical
      Monitoring (USA)

                
	
                  ·

                	
                  Clinical
      Monitoring (USA)

                	
                  ·

                	
                  Pharmacovigilance
      (inc OC AERS set-up/maintenance)

                
	
                  ·

                	
                  Data
      Management

                	
                  ·

                	
                  Medical
      Writing

                
	
                  ·

                	
                  Biostatistics

                	
                  ·

                	
                  Clinical
      Trial Material Distribution
(USA)

                


        

      

    

    


    STUDY
PARAMETERS:

     

    
      
        
          
            
              
                
                  
                    
                      
                        
                          
                            
                              
                                
                                  
                                    
                                      
                                        
                                          
                                            
                                              
                                                
                                                  	
                                                          PARAMETERS: 

                                                        	 	 	 
	
                                                          Number
      of Completed Patients:

                                                        	 	
                                                          44

                                                        	 
	 
      	 	
                                                          (30
      USA patients)

                                                        	 
	
                                                          Number
      of Investigative Sites:

                                                        	 	
                                                          13

                                                        	 
	 
      	 	
                                                          ( 8
      USA)

                                                        	 
	
                                                          Estimated
      Number of Total CRF Pages Per Patient:

                                                        	 	
                                                          150

                                                        	 
	
                                                          Estimated
      Number of Unique CRF Pages Per Patient:

                                                        	 	
                                                          25

                                                        	 
	
                                                          Total
      Number of CRF Pages:

                                                        	 	
                                                          6,600

                                                        	 
	
                                                          Estimated
      Number of Queries:

                                                        	 	
                                                          1,320

                                                        	 
	
                                                          Total
      Number of Serious Adverse Events:

                                                        	 	
                                                          44

                                                        	 
	
                                                          Total
      Number of Face-to-Face Project Meetings

                                                          (alternating
      between AAIPharma and YMB USA):

                                                        	 	
                                                          4
      with PM

                                                          2
      with Team

                                                        	 
	
                                                          Total
      Number of Teleconferences:

                                                        	 	
                                                          47
      with PM/RA (24 inc. Team)

                                                        	 
	
                                                          USA
      SITES

                                                        	 	 	 
	
                                                          Total
      Number of Qualification Site Assessment (QSA)

                                                        	 	 	 
	
                                                          Visits:

                                                        	 	
                                                          To
      be performed during Initiation Visit

                                                        	 
	 
      	 	 	 
	
                                                          Total
      Number of Initiation Visits:

                                                        	 	
                                                          8

                                                        	 
	 
      	 	 	 
	
                                                          Total
      Number of Interim Visits:

                                                        	 	
                                                          Average
      5 two-day Visits per site

                                                        	 
	 
      	 	 	 
	
                                                          Total
      Number of Closeout Visits:

                                                        	 	
                                                          8

                                                        	 
	 
      	 	 	 
	
                                                          Total
      Number of Tables:

                                                        	 	
                                                          30

                                                        	 
	
                                                          Total
      Number of Listings:

                                                        	 	
                                                          25

                                                        	 
	
                                                          Total
      Number of Figures:

                                                        	 	
                                                          5

                                                        	 
	
                                                          Total
      Number of Outputs:

                                                        	 	
                                                          5

                                                        	 


                                                

                                              

                                            

                                          

                                        

                                      

                                    

                                  

                                

                              

                            

                          

                        

                      

                    

                  

                

              

            

          

        

      

    

    


    
      
        	
                AAIPharma/YMB
      USA Work Order #1 R3

              	
                Page
      1 of 5

              
	
                Attachment
      I

              	 
      


      

    


    
      
         


      

      
         


        
          

        

      

      
         


      

    


    TIMELINE

    


    
      
        
          
            
              
                
                  	
                          TIME
      LINE

                        	 	 
      	 
	
                          Project
      Award (LOI executed):

                        	 	
                          August
      27, 2007

                        	 
	
                          Study
      Start-up:

                        	 	
                          3
      months

                        	 
	
                          Patient
      Enrollment Duration:

                        	 	
                          14
      months

                        	 
	
                          Patient
      Treatment Duration:

                        	 	
                          Up
      to 4.5 months (18 weeks)

                        	 
	
                          Follow-up
      Duration:

                        	 	
                          Up
      to 4 months

                        	 
	
                          Database
      Lock:

                        	 	
                          1
      month after last CRF in-house

                        	 
	
                          Draft
      Tables, Listings and Figures1:

                        	 	
                          3
      Weeks from Database Lock

                        	 
	
                          Final
      Tables, Listings and Figures1:

                        	 	
                          2
      Weeks from Receipt of YMB USA’s Comments

                        	 
	
                          Draft
      Report1:

                        	 	
                          4
      Weeks from Final Tables, Listings and Figures

                        	 
	
                          Final
      Report1:

                        	 	
                          2
      Weeks from Receipt of YMB USA’s Comments

                        	 
	
                          TOTAL
      PROJECT DURATION

                        	 	
                          29
      months

                        	 


                

              

            

          

        

      

    

    


    1Assumes
an optimized collaborative process between AAIPharma and YMB USA during
statistical analysis, results reviews, and report planning and
generation.

    


    TASK
OWNERSHIP

    


    Study
Setup (services to achieve the “First Patient Enrolled” milestone)

    


    
      
        
          
            
              
                
                  
                    	
                            Service

                          	 	
                            YMB USA

                            Responsibility

                          	 	
                            AAIPharma

                            Responsibility

                          	 
	
                            Kickoff
      Meeting

                          	 	
                            ü

                          	 	
                            ü

                          	 
	
                            Prepare
      Project Operational Plan (POP)

                          	 	 
      	 	
                            ü

                          	 
	
                            CRF
      Design

                          	 	 
      	 	
                            ü

                          	 
	
                            CRF
      Printing and Shipping

                          	 	 
      	 	
                            ü

                          	 
	
                            Develop
      Model Informed Consent Form

                          	 	 
      	 	
                            ü

                          	 
	
                            Investigator
      Selection

                          	 	
                            ü

                          	 	 
      	 
	
                            Conduct
      Qualifying Site Assessment Visits (USA Sites)

                          	 	 
      	 	
                            Performed
      at

                            Initiation
      Visit

                          	 
	
                            Collect/Review
      Regulatory Documents (USA Sites)

                          	 	 
      	 	
                            ü

                          	 


                  

                

              

            

          

        

      

    

    


    
      
        	
                AAIPharma/YMB
      USA Work Order #1 R3

              	
                Page
      2 of 5

              
	
                Attachment
      I

              	 
      


      

    

     

    
      
         


      

      
         


        
          

        

      

      
         


      

    

    


    
      
        
          
            	
                    Service

                  	 
      	
                    YMB USA

                    Responsibility

                  	 
      	
                    AAIPharma

                    Responsibility

                  	 
	
                    Maintain
      Trial Master File (USA Sites)

                  	 
      	 
      	 
      	
                    ü

                  	 
	
                    File
      Regulatory Documents with FDA

                  	 
      	
                    ü

                  	 
      	 
      	 
	
                    Coordinate
      Investigational Product Packaging/Shipping

                  	 
      	
                    ü

                  	 
      	
                    US
      Sites

                  	 
	
                    ·      Client
      will provide ready-to distribute clinical supplies

                  	 
      	 
      	 
      	 
      	 
	
                    ·      storage
      at 2-8C

                  	 
      	 
      	 
      	 
      	 
	
                    

                      ·      Distribution
      performed at 2-8C w/ temperature monitoring required

                    

                  	 
      	 
      	 
      	 
      	 
	
                    ·      Drug
      return activities and destruction not required

                  	 
      	 
      	 
      	 
      	 
	
                    Assist
      sites with IRB requirements

                  	 
      	 
      	 
      	
                    ü

                  	 
	
                    Negotiate
      Site Agreements

                  	 
      	
                    ü

                  	 
      	 
      	 
	
                    Execute
      Site Agreements

                  	 
      	
                    ü

                  	 
      	 
      	 
	
                    Plan
      and Coordinate Investigators’ Meeting

                  	 
      	
                    ü

                  	 
      	 
      	 
	
                    Attend
      Investigators’ Meeting

                  	 
      	
                    ü

                  	 
      	
                    ü

                  	 
	 
      	 
      	 
      	 
      	
                    5
      attendees

                  	 
	
                    Attend
      Training Meeting

                  	 
      	
                    ü

                  	 
      	
                    ü

                  	 
	
                    Conduct
      Initiation Visits with Medical Monitor

                  	 
      	 
      	 
      	
                    US
      Sites

                  	 
	
                    Develop
      Monitor Guidelines and Source Document Verification Plan
      (SDVP)

                  	 
      	 
      	 
      	
                    ü

                  	 
	
                    Database
      Design

                  	 
      	 
      	 
      	
                    ü

                  	 
	
                    Data
      Management Operational Plan (DMOP)

                  	 
      	 
      	 
      	
                    ü

                  	 
	
                    Generate
      Statistical Analysis Plan

                  	 
      	 
      	 
      	
                    ü

                  	 


          

        

      

    

    


    Ongoing Study
Management (Services from First Patient Enrolled through Database
Lock)  

    


    
      
        
          
            
              
                	
                        Service

                      	 
      	
                        YMB USA

                        Responsibility

                      	 
      	
                        AAIPharma

                        Responsibility

                      	 
	
                        Provide
      Interim Monitoring Visits (USA Sites)

                      	 
      	 
      	 
      	
                        ü

                      	 
	
                        Provide
      Ongoing Site Management Services (USA

                      	 
      	 
      	 
      	
                        ü

                      	 
	
                        Sites)

                      	 
      	 
      	 
      	 
      	 
	
                        Administer
      Payments of Investigator Grants

                      	 
      	
                        ü

                      	 
      	 
      	 
	
                        Provide
      Status Reports to YMB USA

                      	 
      	
                        ü

                      	 
      	 
      	 
	
                        Provide
      Medical Management (USA)

                      	 
      	 
      	 
      	
                        ü

                      	 
	
                        Set-up
      and Maintain Oracle AERS Database

                      	 
      	 
      	 
      	
                        ü

                      	 
	
                        Provide
      SAE Management

                      	 
      	 
      	 
      	
                        ü

                      	 
	
                        Preparation
      of SAE narratives

                      	 
      	 
      	 
      	
                        ü

                      	 


              

            

          

        

      

    

    


    
      
        
          	
                  AAIPharma/YMB
      USA Work Order #1 R3

                  Attachment
      I

                	
                  Page
      3 of 5

                


        

      

    

     

    
      
         


      

      
         


        
          

        

      

      
         


      

    


    


    
      
        
          
            
              
                	
                        Service

                      	 
      	
                        YMB USA

                        Responsibility

                      	 
      	
                        AAIPharma

                        Responsibility

                      	 
	
                        Filing
      of SAE Reports with the FDA

                      	 
      	
                        ü

                      	 
      	 
      	 
	
                        Participate
      in Project Team Meetings

                      	 
      	
                        ü

                      	 
      	
                        ü

                      	 
	
                        Participate
      in Teleconferences

                      	 
      	
                        ü

                      	 
      	
                        ü

                      	 
	
                        Provide
      Quality Assurance Site Audits

                      	 
      	 
      	 
      	
                        ü

                      	 
	
                        CRF
      and Query Scanning, Tracking, and Storage

                      	 
      	 
      	 
      	
                        ü

                      	 
	
                        Data
      Entry

                      	 
      	 
      	 
      	
                        ü

                      	 
	
                        Data
      Verification

                      	 
      	 
      	 
      	
                        ü

                      	 
	
                        Integration
      of External Electronic Data

                      	 
      	 
      	 
      	
                        ü

                      	 
	
                        Data
      Validation

                      	 
      	 
      	 
      	
                        ü

                      	 
	
                        Data
      Coding

                      	 
      	 
      	 
      	
                        ü

                      	 
	
                        SAE
      Report Reconciliation against CRF Data

                      	 
      	 
      	 
      	
                        ü

                      	 
	
                        Database
      Quality Control Audit

                      	 
      	 
      	 
      	
                        ü

                      	 
	
                        Provide
      Clean, Locked Database to YMB USA

                      	 
      	 
      	 
      	
                        ü

                      	 
	
                        Quality
      Assurance Site Audits

                      	 
      	 
      	 
      	
                        ü

                      	 
	 
      	 
      	 
      	 
      	
                        Optional

                      	 
	
                        Advance
      Planning for Study Report

                      	 
      	
                        ü

                      	 
      	
                        ü

                      	 


              

            

          

        

      

    

    


    
      	
              AAIPharma/YMB
      USA Work Order #1 R3

            	
              Page
      4 of 5

            
	
              Attachment
      I

            	 
      


    

     

    
      
        
        

      

      
        
        

        
          

        

      

      
        
        

      

    

     

    Study
Closeout Services (Services from Database Lock to final
Deliverable)

    


    
      
        
          
            
              	
                      Service

                    	 
      	
                      YMB USA

                      Responsibility

                    	 
      	
                      AAIPharma

                      Responsibility

                    	 
	
                      Conduct
      Study Closeout Visits (USA Sites)

                    	 
      	 
      	 
      	
                      ü

                    	 
	
                      Generate
      Statistical Tables, Listings, and Figures

                    	 
      	 
      	 
      	
                      ü

                    	 
	
                      Attend
      Results Review Meeting

                    	 
      	
                      ü

                    	 
      	
                      ü

                    	 
	
                      Generate
      Draft Clinical Study Report (CSR)

                    	 
      	 
      	 
      	
                      ü

                    	 
	
                      Comment
      on Draft CSR

                    	 
      	
                      ü

                    	 
      	 
      	 
	
                      Finalize
      Clinical Study Report

                    	 
      	 
      	 
      	
                      ü

                    	 
	
                      Prepare
      and Transfer SAS Code

                    	 
      	 
      	 
      	
                      ü

                    	 
	
                      Study
      Closeout Meeting

                    	 
      	
                      ü

                    	 
      	
                      ü

                    	 


            

          

        

      

    

    


    
      
        	
                AAIPharma/YMB
      USA Work Order #1 R3

                Attachment
      I

              	
                Page
      5 of 5

              


      

    

     

    
      
         


      

      
         


        
          

        

      

      
         


      

    


    ATTACHMENT
II to Work Order #1

    Budget
and Payment Terms for the Final Scope of Work

     

    ESTIMATED
BUDGET

    


    [Intentionally
Left Blank]

    


    AAIPharma/YMB
USA Work Order #1 R2

    Attachment
II


    
      
         


      

      
         


        
          

        

      

      
         


      

    


    ESTIMATED
BUDGET

    


    YM
Biosciences - 07-138.R3 dated November 8, 2007

    #Sites

    #CRFs

    


    
      
        	 	44	 	
                Total
      Enrolled Patients

              
	 	30	 	
                Total
      US Patients

              
	 	8	 	
                US
      Sites

              
	 	6,600	 	
                Total
      CRF Pages

              
	 	29	 	
                Months
      Study Duration

              


      

    

    


    
      
        
          
            
              
                
                  	 
      	 
      	
                          ESTIMATED BUDGET

                        	 
	
                          PROJECT
      MANAGEMENT

                        	 
      	 
      	 
      	
                          189,441

                        	 
	
                          PROJECT
      COORDINATION (29 months)

                        	 
      	
                          149,497

                        	 
      	 
      	 
	
                          PROJECT
      MEETINGS AND CONFERENCE CALLS

                        	 
      	
                          39,944

                        	 
      	 
      	 
	 
      	 
      	 
      	 
      	 
      	 
	
                          STUDY
      SETUP

                        	 
      	 
      	 
      	
                          63,552

                        	 
	
                          REGULATORY
      DOCUMENT COLLECTION AND PROCESSING

                        	 
      	
                          14,692

                        	 
      	 
      	 
	
                          PROJECT
      TEAM TRAINING AND KICK-OFF MEETING

                        	 
      	
                          7,303

                        	 
      	 
      	 
	
                          INVESTIGATORS
      MEETINGS (US Sites Face-to-Face)

                        	 
      	 
      	 
      	 
      	 
	
                          ATTENDANCE
      & PARTICIPATION

                        	 
      	
                          21,136

                        	 
      	 
      	 
	
                          COORDINATION
      FEE

                        	 
      	
                          0

                        	 
      	 
      	 
	
                          CRF
      DESIGNS AND INSTRUCTIONS

                        	 
      	
                          20,422

                        	 
      	 
      	 
	
                          ADMINISTRATION
      & PAYMENT OF LABORATORY

                        	 
      	
                          0

                        	 
      	 
      	 
	
                          ADMINISTRATION
      OF INVESTIGATOR GRANTS

                        	 
      	
                          0

                        	 
      	 
      	 
	 
      	 
      	 
      	 
      	 
      	 
	
                          CLINCAL/MEDICAL
      AFFAIRS

                        	 
      	 
      	 
      	
                          603,600

                        	 
	
                          QSA/INITIATION
      VISITS (8)

                        	 
      	
                          21,093

                        	 
      	 
      	 
	
                          MEDICAL
      MONITOR TO ATTEND QSA/INITIATION VISITS

                        	 
      	
                          34,367

                        	 
      	 
      	 
	
                          INTERIM
      MONITORING VISITS (Average 5 two-day visits per site)

                        	 
      	
                          135,965

                        	 
      	 
      	 
	
                          CLOSEOUT
      VISITS (8)

                        	 
      	
                          15,916

                        	 
      	 
      	 
	
                          STATUS
      REPORTS

                        	 
      	
                          8,893

                        	 
      	 
      	 
	
                          MEDICAL
      MANAGEMENT

                        	 
      	
                          27,123

                        	 
      	 
      	 
	
                          SAE
      MANAGEMENT SET-UP AND MAINTENANCE (Oracle AERS)

                        	 
      	
                          13,597

                        	 
      	 
      	 
	
                          SAE
      MANAGEMENT

                        	 
      	
                          76,553

                        	 
      	 
      	 
	
                          SAE
      NARRATIVES (Includes MedWatch/CIOMS reports)

                        	 
      	
                          17,248

                        	 
      	 
      	 
	
                          SITE
      MANAGEMENT

                        	 
      	
                          70,646

                        	 
      	 
      	 
	
                          CLINICAL
      REGULATORY SITE SUPPORT

                        	 
      	
                          56,061

                        	 
      	 
      	 
	
                          CLINICAL
      PROJECT COORDINATION

                        	 
      	
                          126,138

                        	 
      	 
      	 
	 
      	 
      	 
      	 
      	 
      	 
	
                          DATA
      MANAGEMENT & CLINICAL DATA SYSTEMS

                        	 
      	 
      	 
      	
                          281,714

                        	 
	
                          DATA
      MANAGEMENT OPERATIONAL PLAN

                        	 
      	
                          16,260

                        	 
      	 
      	 
	
                          DATABASE
      DESIGN, PROGRAMMING AND TESTING

                        	 
      	
                          55,686

                        	 
      	 
      	 
	
                          DATA
      ENTRY AND VERIFICATION

                        	 
      	
                          34,555

                        	 
      	 
      	 
	
                          DICTIONARY
      CODING

                        	 
      	
                          8,141

                        	 
      	 
      	 
	
                          CRF
      AND QUERY TRACKING & INVENTORY VIA SCANNING

                        	 
      	
                          7,443

                        	 
      	 
      	 
	
                          DATA
      VALIDATION INCLUDING QUERY GENERATION & RESOLUTION

                        	 
      	
                          50,326

                        	 
      	 
      	 
	
                          MEDICAL
      REVIEW OF CRFs

                        	 
      	
                          20,674

                        	 
      	 
      	 
	
                          DATABASE
      QUALITY CONTROL AUDIT

                        	 
      	
                          10,526

                        	 
      	 
      	 
	
                          EXTERNAL
      DATA INTEGRATION

                        	 
      	
                          1,300

                        	 
      	 
      	 
	
                          DATA
      MANAGEMENT PROJECT COORDINATION

                        	 
      	
                          57,619

                        	 
      	 
      	 
	
                          ADMINISTRATIVE

                        	 
      	
                          12,570

                        	 
      	 
      	 
	 
      	 
      	 
      	 
      	 
      	 
	
                          BIOSTATISTICAL/REPORT
      PREPARATION SERVICES

                        	 
      	 
      	 
      	
                          143,401

                        	 
	
                          STATISTICAL
      ANALYSIS PLAN

                        	 
      	
                          13,069

                        	 
      	 
      	 
	
                          STATISTICAL
      TABLES, LISTINGS & PROGRAMMING

                        	 
      	
                          52,062

                        	 
      	 
      	 
	
                          ANALYSIS
      PRODUCTION

                        	 
      	
                          19,497

                        	 
      	 
      	 
	
                          INTEGRATED
      CLINICAL/STATISTICAL REPORT

                        	 
      	
                          43,780

                        	 
      	 
      	 
	
                          RESULTS
      REVIEW MEETING

                        	 
      	
                          3,157

                        	 
      	 
      	 
	
                          BIOSTATISTICAL/REPORT
      PROJECT COORDINATION

                        	 
      	
                          11,835

                        	 
      	 
      	 
	 
      	 
      	 
      	 
      	 
      	 
	
                          TOTAL
      ESTIMATED BUDGET

                        	 
      	
                          1,281,709

                        	 
      	 
      	 
	 
      	 
      	 
      	 
      	 
      	 
	
                          ADDITIONAL
      SERVICES

                        	 
      	 
      	 
      	 
      	 
	
                          CLINICAL
      TRIAL MATERIAL DISTRIBUTION TO US SITES

                        	 
      	
                          14,900

                        	 
      	 
      	 
	 
      	 
      	 
      	 
      	 
      	 
	
                          TOTAL
      ESTIMATED BUDGET EXCLUSIVE OF PASS THROUGH EXPENSES

                        	 
      	
                          1,296,609

                        	 
      	 
      	 
	 
      	 
      	 
      	 
      	 
      	 
	
                          ESTIMATED
      PASS THROUGH EXPENSES

                        	 
      	 
      	 
      	
                          66,850

                        	 
	
                          INVESTIGATOR
      MEETING (incidentals @$100/attendee)

                        	 
      	
                          500

                        	 
      	 
      	 
	
                          MONITOR
      TRAVEL

                        	 
      	
                          46,000

                        	 
      	 
      	 
	
                          MEDICAL
      MONITOR TRAVEL (8 VISITs)

                        	 
      	
                          6,000

                        	 
      	 
      	 
	
                          CRF
      PRINTING AND SHIPPING

                        	 
      	
                          10,600

                        	 
      	 
      	 
	
                          PROJECT
      MEETING EXPENSES

                        	 
      	
                          3,750

                        	 
      	 
      	 
	 
      	 
      	 
      	 
      	 
      	 
	
                          TOTAL
      ESTIMATED BUDGET

                        	 
      	
                          1,363,459

                        	 
      	 
      	 
	 
      	 
      	 
      	 
      	 
      	 
	
                          OPTIONAL
      COSTS

                        	 
      	 
      	 
      	 
      	 
	
                          CLINICAL
      INTERIM MONITORING

                        	 
      	 
      	 
      	 
      	 
	
                          ADDITIONAL
      VISIT PER PATIENT (From 1 to 2 Visits per Patient)

                        	 
      	
                          103,746

                        	 
      	 
      	 
	
                          SITE
      VISIT TRAVEL

                        	 
      	
                          30,000

                        	 
      	 
      	 
	
                          QUALITY
      ASSURANCE

                        	 
      	 
      	 
      	 
      	 
	
                          INVESTIGATOR
      SITE VISITS

                        	 
      	
                          10,149

                        	 
      	 
      	 
	
                          SITE
      VISIT TRAVEL

                        	 
      	
                          1,000

                        	 
      	 
      	 


                

              

            

          

        

      

    

    


    AAIPharma/YMB
USA Work Order #1 R2

    Attachment
II


    
      
         


      

      
         


        
          

        

      

      
         


      

    


    Payment
Schedule

    YM
Biosciences

    YMB1000/009

    


    
      
        
          	 
      	 
      	
                  First Budget

                	 
      
	
                  Direct Costs:

                	 
      	
                  USD

                	 
      
	 
      	 
      	 	 
      
	
                  Execution
      of WorkOrder 

                	 
      	
                  $

                	
                  129,661

                	 
      
	
                  Milestones:

                	 
      	 
      	 
      	 
      
	
                  Monthly
      Maintenance Fee (Project Management, Site Management, PVG, QA and Medical
      Overview)

                	 
      	 
      	 
      	 
      
	
                  $13,083.20/month
      for 29 months (Sept-07-Jan-07) 

                	 
      	
                  $

                	
                  379,413

                	 
      
	
                  Clinical:

                	 
      	 
      	 
      	 
      
	
                  Completion
      of Base Documents

                	 
      	
                  $

                	
                  26,381

                	 
      
	
                  First
      Site Initiated

                	 
      	
                  $

                	
                  31,930

                	 
      
	
                  100%
      Sites Initiated

                	 
      	
                  $

                	
                  95,789

                	 
      
	
                  First
      Patient Enrolled

                	 
      	
                  $

                	
                  60,835

                	 
      
	
                  20%
      Monitoring Visits Completed

                	 
      	
                  $

                	
                  60,835

                	 
      
	
                  40%
      Monitoring Visits Completed

                	 
      	
                  $

                	
                  60,835

                	 
      
	
                  60%
      Monitoring Visits Completed

                	 
      	
                  $

                	
                  60,835

                	 
      
	
                  80%
      Monitoring Visits Completed

                	 
      	
                  $

                	
                  60,835

                	 
      
	
                  100%
      Monitoring Visits Completed

                	 
      	
                  $

                	
                  60,835

                	 
      
	
                  All
      Sites Closed-out

                	 
      	
                  $

                	
                  37,028

                	 
      
	
                  Database
      Set-Up

                	 
      	
                  $

                	
                  44,573

                	 
      
	
                  50%
      CRFs Completed

                	 
      	
                  $

                	
                  44,573

                	 
      
	
                  100%
      CRFs Completed

                	 
      	
                  $

                	
                  44,573

                	 
      
	
                  Database
      Lock

                	 
      	
                  $

                	
                  44,573

                	 
      
	
                  Clinical
      Study Report

                	 
      	
                  $

                	
                  53,108

                	 
      
	
                  Total
      Direct Costs

                	 
      	
                  $

                	
                  1,296,609

                	 
      


        

      

    

    


    AAIPharma/YMB USA Work Order #1 R2

    Attachment
II